Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics Inc (EWTX, Financial), sold 10,000 shares of the company on February 9, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $20.03 per share, resulting in a total value of $200,300.
Edgewise Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare muscle disorders. The company's proprietary platform is designed to modulate muscle function with the aim of addressing diseases characterized by excessive or diminished muscle activity.
Over the past year, the insider has engaged in the sale of 11,747 shares and has not made any purchases of the company's stock. The recent transaction is part of a series of sales by the insider, indicating a consistent pattern of share disposals over the period.
The insider transaction history for Edgewise Therapeutics Inc reveals a trend of more insider sales than purchases in the past year. There have been 11 insider sells and only 3 insider buys during this timeframe.
On the date of the insider's most recent transaction, shares of Edgewise Therapeutics Inc were trading at $20.03, giving the company a market capitalization of $1.827 billion.
Investors often monitor insider transactions as part of their due diligence process, as these can provide insights into insiders' perspectives on the value of the company's stock. However, it is important to consider a wide range of factors when evaluating the implications of insider trading activity.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
